Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 7.36
+0.01 (0.14%)
Aug 19, 2026, 9:54 AM CST
Pharmigene Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 187.88 | 199.89 | 116.53 | 132.71 | 133.8 | 129.35 |
Revenue Growth | -6.01% | 71.53% | -12.19% | -0.82% | 3.44% | 27.63% |
Gross Profit Gross Profit Growth | 52.63 | 56.43 | 41.47 | 42.54 | 44.73 | 46.05 |
Operating Income Operating Income Growth | -44.82 | -54.96 | -85.23 | -59.19 | -44.45 | -22.74 |
Net Income Net Income Growth | -52.27 | -73 | -82.86 | -72.65 | -42.72 | -23.43 |
Earnings Per Share EPS Growth | -1.04 | -1.45 | -1.64 | -1.60 | -0.98 | -0.54 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Taiwan Taiwan Growth | 134.85 | 103.56 | 116.39 | 119.47 | 116.18 |
Asia Asia Growth | 2.35 | 8.95 | 13.02 | 9.51 | 10.6 |
Europe Europe Growth | 0.16 | 0.59 | 0.54 | 3.75 | 0.92 |
America America Growth | 62.54 | 3.44 | 2.75 | 1.07 | 1.66 |
Total Total Growth | 199.89 | 116.53 | 132.71 | 133.8 | 129.35 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 92.58 | 85.46 | 158.64 | 160.78 | 195.59 | 239.09 |
Total Debt Total Debt Growth | 636.45 | 655.05 | 616.49 | 571.1 | 9.43 | 14.74 |
Net Cash (Debt) Net Cash Growth | -543.86 | -569.6 | -457.84 | -410.32 | 186.16 | 224.35 |
Net Cash Growth | - | - | - | - | -17.02% | -18.67% |
Net Cash Per Share Net Cash Per Share Growth | -10.79 | -11.29 | -9.07 | -9.02 | 4.28 | 5.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -4.14 | -66.99 | -44.82 | -77.54 | -23.47 | -19.31 |
Capital Expenditures CapEx Growth | -2.23 | -8.34 | -64.6 | -665.31 | -10.5 | -12.67 |
Free Cash Flow Free Cash Flow Growth | -6.38 | -75.33 | -109.42 | -742.85 | -33.96 | -31.98 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 28.01% | 28.23% | 35.59% | 32.06% | 33.43% | 35.60% |
Operating Margin | -23.86% | -27.49% | -73.13% | -44.60% | -33.22% | -17.58% |
Pretax Margin | -27.82% | -36.50% | -71.08% | -54.73% | -31.92% | -18.38% |
Profit Margin | -27.82% | -36.52% | -71.11% | -54.74% | -31.92% | -18.12% |
FCF Margin | -3.40% | -37.69% | -93.90% | -559.76% | -25.38% | -24.72% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 1.88 | 2.50 | 6.17 | 7.87 | 6.45 | 7.29 |